Diovan, marketed by Novartis, had annual sales of about $1.8 billion in the US, according to IMS data as of October 2014.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has announced the launch of the generic equivalent of Diovan (Valsartan) tablets in the US, following Food and Drug Administration (FDA) approval. Diovan treats high blood pressure and is used by heart disease patients.
Diovan, marketed by Novartis Pharmaceuticals, had annual sales of about $1.8 billion in the US, according to IMS data as of October 2014.
Only yesterday, Teva announced that it was launching two new generic versions of antibiotics in the US.
Published by Globes [online], Israel business news - www.globes-online.com - on January 7, 2015
© Copyright of Globes Publisher Itonut (1983) Ltd. 2015
Teva